Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues

Silvia Fogacci, Federica Fogacci, Elda Favari, Peter P. Toth, Claudio Borghi, Arrigo F.G. Cicero

a. Hypertension and Cardiovascular Risk Research Group, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Bologna, Italy

b. Department of Food and Drug, University of Parma, Parma, Italy

c. CGH Medical Center, Sterling, IL, and Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Declarations of interest: none

Abbreviations: ACOG= American College of Obstetricians and Gynecologists; AHA= American Heart Association; CCB= Calcium channel blockers; COVID-19= Coronavirus-19; CV= Cardiovascular; ESC= European Society of Cardiology; LMWH= Low molecular weight heparin; NSAIDs= Non-steroidal anti-inflammatory drugs; SARS-CoV-2= Severe acute respiratory syndrome Coronavirus 2.

Corresponding author:
Arrigo F.G. Cicero, MD, PhD
Medical and Surgical Sciences Department
Sant’Orsola-Malpighi University Hospital
U.O. Medicina Interna Borghi - Via Albertoni, 15
40138 Bologna - Italy
Tel.: ++39 512142224 - Fax: ++39 51391320
E-mail: arrigo.cicero@unibo.it
Abstract

Aims: Coronavirus-19 infection (COVID-19) continues to spread throughout the world. It is known that among patients with hypertension, diabetes, chronic respiratory disease, or cardiovascular (CV) diseases, COVID-19 is associated with greater morbidity and mortality compared to patients without these conditions. This correlation is of great importance in pregnant women affected by COVID-19, since it usually leads to the development of a serious clinical complication. In particular, managing hypertensive disorders in pregnancy can be problematic because anti-hypertensive medications may interact pharmacologically with drugs used to treat COVID-19. This review focuses on the safety of drug treatment for COVID-19 in pregnant women treated with anti-hypertensive medication.

Methods and results: Several databases were searched to identify relevant literature. A few anti-hypertensive drugs and antithrombotic treatments are known for having a beneficial effect in the management of hypertension and hypertensive disorders in pregnancy. In this review, we focus on the expected drug-drug interactions with the experimental agents mostly used treat COVID-19.

Conclusions: The current indication for the management of hypertension-related disorders in pregnancy maintain their validity, while the risk of pharmacological interaction with the currently tested anti-SARS-CoV-2 medications is relatively low.

Keywords: SARS-CoV-2; Coronavirus-19; COVID-19; pregnancy; hypertension; antihypertensive treatment
1. INTRODUCTION

Coronavirus disease (COVID-19), caused by the highly transmissible severe acute respiratory virus Coronavirus 2 (SARS-CoV-2), continues to spread throughout the world [1]. The virus is primarily spread through close human contact via aerosolized droplets of saliva or mucus secretions [2]. Its main feature is infection of the respiratory system in association with cough, fever and typical changes in radiographic studies that can lead to acute respiratory distress syndrome, cardiovascular (CV) events such as myocardial infarction, myocarditis, fulminant heart failure and lethal arrhythmias, and such neurovascular events as ischemic stroke and encephalopathy. Pregnant women are considered a high-risk group due to their altered immunological and physiological status [3-5]. Viral respiratory illnesses frequently develop during pregnancy; hence, pregnant women have greater vulnerability for contracting a SARS-CoV-2 infection [6,7]. As a matter of fact, physiological hormonal changes in pregnant women, such as the progesterone-mediated action on nasal mucosa, have been demonstrated to increase the probability of contracting the disease compared to the general population [7].

Very few studies are available concerning the effect of COVID-19 on pregnancy and fetal outcomes [8]. The maternal-fetal interface was analyzed in different clinical settings, and no evidence of vertical COVID-19 transmission was seen in pregnant women in the third trimester of pregnancy [9-11]. Due to limited scientific evidence regarding pregnancy and COVID-19, some official statements have been made referring to SARS CoV-1 [12]. Some previous studies about SARS suggest women may need prioritized medical care since COVID-19 infection during pregnancy may lead to maternal and fetal complications, such as spontaneous miscarriage, preterm birth, intrauterine growth restriction, premature rupture of membranes, fetal tachycardia and fetal distress, multiple organ injury and admission to intensive care units [10,12-14]. Nevertheless, what is clear is that more
studies are needed regarding COVID-19 and pregnancy, considering the fact that it affects the well-being of mothers and their babies [6]. For this reason, accurate hygiene and social information must be guaranteed to pregnant women and their families in order to prevent SARS-CoV-2 infection [2].

It is known that among patients with hypertension, diabetes, chronic respiratory disease, or CV diseases, SARS-CoV-2 infection is associated with greater morbidity and mortality compared to patients without these conditions [11,15]. This correlation is of great importance in pregnant women affected by COVID-19, since it usually leads to the development of a serious clinical complication [6]. Regarding hypertensive disorders in pregnancy there are very few drugs available with a controversial security profile, that sometimes pharmacologically interact with the ones tested to treat COVID-19 [16]. In particular, the anti-COVID-19 medications for which there are currently more evidence are low molecular weight heparin (LMWH), lopinavir/ritonavir, hydroxychloroquine and chloroquine [7,15].

The purpose of the current review is to highlight the safety of drug treatment for COVID-19 in pregnant women treated with anti-hypertensive medications.

2. MATERIAL AND METHODS

For the purpose of this review, authors identified trials in both MEDLINE (National Library of Medicine, Bethesda, Maryland, MD, USA; January 1980 to July 2020) and the Cochrane Register of Controlled Trials (The Cochrane Collaboration, Oxford, UK). The terms ‘SARS-CoV-2’, ‘severe acute respiratory syndrome’, ‘Coronavirus disease’, ‘COVID-19’, ‘lopinavir/ritonavir’, ‘chloroquine’, ‘hydroxychloroquine’, ‘aspirin’, ‘methyldopa’, ‘hydralazine’, ‘beta-blockers’, ‘labetalol’, ‘metoprolol’, ‘atenolol’, ‘pindolol’, ‘calcium channel blockers’,
‘diltiazem’, ‘nifedipine’, ‘verapamil’, ‘magnesium sulfate’, ‘low molecular weight heparin’, ‘LMWH’, ‘hypertension’, ‘pre-eclampsia’, ‘preeclampsia’, ‘clinical trial’, and ‘human’ were incorporated into an electronic search strategy. The references of the identified studies and review articles were reviewed to look for additional studies of interest. The authors reviewed all of the citations retrieved from the electronic search to identify potentially relevant articles for this review.

3. RESULTS

A few anti-hypertensive drugs and antithrombotic treatments are known for having a beneficial effect in the management of hypertension and hypertensive disorders in pregnancy. In this review, we focus on the expected drug-drug interactions with the experimental agents most often used to treat SARS-CoV-2 infection (Figure 1).

1 Aspirin. In accordance with the European Society of Cardiology (ESC) guidelines for the management of CV diseases during pregnancy, 100-150 mg/day acetylsalicylic acid (aspirin) should be recommended to pregnant women with a high or moderate risk to develop pre-eclampsia (class I; level of evidence A) [17]. Similarly, the American College of Obstetricians and Gynecologists (ACOG) recommends that these patients take 81 mg/day of aspirin (level of evidence A) [18].

In the general population, non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, are reported to negatively affect the lungs, worsening a pre-existing pulmonary infection [19,20]. For this reason, some investigators brought into question the safety of aspirin treatment in pregnancy during the COVID-19 pandemic [21]. Taking into account that significant data about aspirin intake and aggravation of COVID-19 symptoms in pregnancy are lacking, the same authors agree that the benefits of aspirin prophylaxis in high risk women for hypertensive disorders outweigh the potential dangers posed by the
virus [21]. In this perspective, it is also worth to evidence a possible effect of NSAIDs on induction of MAP Kinase Phosphatase 1, leading the inhibition of inflammatory gene expression [22]. Moreover, we have also to consider a possible interaction between aspirin and LMWH on risk of bleeding [23]. On the other side, there is no evidence that aspirin interacts with medications currently being evaluated for treating SARS-CoV-2 infection [24].

3.2 Methyldopa. Methyldopa is an alpha-2 adrenergic agonist with both central and peripheral nervous system effects. Together with labetalol and calcium antagonists, methyldopa is one of the drugs of choice recommended by ESC for the treatment of hypertension in pregnant women (class I; level of evidence B) [17]. In accordance with the American Heart Association (AHA) recommendations [25], methyldopa should only be prescribed in cases of severe hypertension during pregnancy, considering potential maternal and fetal side effects (class I; level of evidence A).

In vitro, chloroquine and hydroxychloroquine are aminoquinolone derivatives that have antiviral activity against the SARS-CoV-2 [26-29]; however, efficacy data in humans are still preliminary. Compared to chloroquine, hydroxychloroquine has a much better safety profile [30], and has demonstrated promising capacity to prevent pre-eclampsia [31]. In clinical practice, methyldopa is often prescribed to women affected by systemic lupus erythematosus treated with hydroxychloroquine to prevent flares [32]. The co-administration of methyldopa and hydroxychloroquine is considered to be safe in hypertensive pregnant women infected with SARS-CoV-2.

3.3 Beta-blockers. Among beta-adrenergic receptor blockers, ESC recommends the use of labetalol as first-line therapy in pregnant women with hypertension (class I; level of evidence C) [17], while AHA suggests atenolol (class III; level of evidence B), pindolol, metoprolol and labetalol as first-line therapies (class IIa; level of evidence B) [25]. ACOG
recommends labetalol therapy in urgent blood pressure control in pregnancy [18]. Third-
generation beta-blockers have also been shown to prevent bronchial asthma attacks and
respiratory dysfunction. The release of nitric oxide, antioxidant action and other
mechanisms underlying the vasodilating action of these drugs may be responsible for the
beneficial therapeutic effects of these agents [33]. However, these agents have never
been tested in pregnant women.

In pregnant women, the combination of beta-blockers and LMWH is the recommended
treatment for atrial fibrillation [34]. In this context, we can reasonably expect the
combination of beta-blockers and heparin to be safely administered in hypertensive-
treated pregnant women infected by SARS-CoV-2. This is certainly of great interest, since
LMWH seems to mitigate the pulmonary coagulopathy often promulgated by the virus
[35,36]. In contrast, the simultaneous administration of beta-blockers and
hydroxychloroquine (or chloroquine) requires close electrocardiographic monitoring due to
the risk of QT prolongation [37].

3.4 Hydralazine. Hydralazine hydrochloride is a hydrazine derivative vasodilator drug. In
light of the ACOG recommendations, hydralazine is one of the drugs used for urgent blood
pressure control in pregnancy [18]. AHA also recommends it in hypertensive-treated
women (class III; level of evidence B) [25]. To date, there is a lack of validated studies
evaluating the interaction between hydralazine and investigational drugs used for treating
SARS-CoV-2 infection while NSAIDs could reduce its efficacy by inhibiting the
prostacyclin-related vasodilation[38].

3.5 Calcium channel blockers. Calcium channel blockers (CCB) are another group of
anti-hypertensive drugs recommended by ESC (level of evidence C) [17] and AHA (class I;
level of evidence A) [25], whereas ACOG advises nifedipine administration only in the
setting of hypertensive urgency [18].
During the current pandemic, questions have been raised about potential drug-to-drug interactions with treatments for SARS-CoV-2 infection. A variety of antiretroviral therapies are being tested to treat COVID-19 [3,39-41]. The co-administration of nifedipine and lopinavir/ritonavir is potentially toxic linked, to their common cytochrome P450 3A4 related metabolism [42,43], occasionally causing serious side effects such as tachycardia, hypotension, headache and peripheral edema [43]. Considering the safety profile of combining nifedipine and lopinavir/ritonavir in non-pregnant women, we can reasonably expect a toxic effect in pregnancy as well [44].

3.6 **Low molecular weight heparin.** LMWH has been shown to prevent pre-eclampsia in high-risk pregnant women by improving endothelial function in the vasculature [45,46]. Moreover, LMWH inhibits endothelial inflammation [47], making it potentially useful for treatment of SARS-CoV-2 infection.

In accordance with the latest ESC guidelines for the management of CV disease during the COVID-19 pandemic, drug-drug interactions should be considered before administering azithromycin in patients treated with LMWH [37], despite possible beneficial effects by azithromycin in patients infected with SARS-CoV-2 [48]. In contrast, chloroquine, hydrochloroquine and lopinavir/ritonavir do not have any clinically significant interactions with LMWH [37].

3.7 **Magnesium sulfate.** Intravenous magnesium sulfate is recommended for preventing eclampsia and treating seizures as suggested by ACOG (level of evidence A) [18] and ESC [17] guidelines. According to a case-control study, its co-administration with LMWH shows better results than magnesium sulfate alone in treating severe pre-eclampsia [49]. There are no no contraindications to combined treatment in hypertensive pregnant women infected with SARS-CoV-2 [50].
3.8 Vitamins. Though vitamin D supplementation is not recommended by international guidelines, a recent meta-analysis shows it may prevent pre-eclampsia in pregnancy [51]. From the COVID-19 point of view, it seems to have a role in the pre-clinical phase in strengthening the immune system, especially in cases of deficiency [52]. Furthermore, several studies have shown antiviral effects of vitamin D, which can interfere directly with viral replication, but also can act in an immunomodulatory and anti-inflammatory way [53]. So far, low serum levels of vitamin D have been linked to increased morbidity and mortality in COVID-19 patients [54,55]. Ahmed et al. have reported the case of a 29-year woman with diabetes and vitamin D deficiency who died from thrombotic complications during SARS-CoV-2 infection [56].

In addition to vitamin D, vitamin C is not included in international recommendations, though its deficiency has been associated with an increased risk of pre-eclampsia [57]. Its role in preventing hypertensive disorders in pregnancy is still unclear and needs to be further investigated [58]. In the course of the SARS-CoV-2 pandemic, vitamin C serum levels are reported to decrease during infection and the requirement for supplementation increases accordingly [59]. A number of ongoing clinical trials will provide additional information on the impact of vitamin administration as a component of supportive care in SARS-CoV-2 infection [60,61].

4. DISCUSSION

The general advice for pregnant women is to avoid pharmacological treatments, in particular since rarely the safety profile of drugs has been systematically evaluated in this frail patient population [62]. Considering that available data on COVID-19 in pregnant patients do not provide a clear conclusion as regards clinical implications for mother and fetus [62], decision-making
processes in clinical practice need to be based on well-known similar prognostic models. In this context, in order to study the potential drug-drug interactions it is possible to refer to particular affections in pregnancy in which the anti-hypertensive treatment has just been tested along with drugs currently used against SARS-CoV-2. For example, cohorts of hypertensive pregnant women affected by HIV can be taken into exam to predict the clinical outcome of protease inhibitors and CCB association [63]. In the same way chloroquine and hydrochloroquine effect along with methyldopa can be usefully considered in cohorts of pregnant women with rheumatological diseases and gestational hypertension [32]. There is no doubt that data on long-term safety regarding all the above-discussed treatment combinations are needed, but until more evidence become available, it is necessary to rely on previous clinical experience and not prioritize the treatment of COVID-19 over that of hypertension, as it can also result in potentially fatal complications [64]. On the other side, even if renin-angiotensin system inhibitors seem to improve the clinical outcomes of SARS-CoV-2 patients with hypertension [65,66], they are contraindicated during pregnancy because of teratogenesis risk [17]. Finally, it must be taken into account that even though several clinical trials have been initiated to assess potentially promising therapies for COVID-19, pregnant and breastfeeding women were excluded from almost all these studies [67]. Obviously, this will cause a delay in identifying the most appropriate treatment, though the choice is in some respects understandable.

Future research should focus on drugs protecting the endothelium from the damage induced by SARS-CoV-2 infection.[68] In particular, cell adhesion molecules (CAMs), including CD209L/L-SIGN and CD209/DC-SIGN, could be a relevant role in SARS-CoV-2 infection and other related viruses, consequently been possible therapeutic targets.[69] Inhibition of IL-6 and the Janus Kinase, signal transducer and activator of transcription proteins pathway (JAK/STAT), could be also favorable targets.[70]
To date, the only safe medical care showing benefit in treating the virus in pregnant patients is pressurized air enriched with oxygen, intravenous hydration, nutritional supports and electrolyte balance, which are supposed to help and improve the oxygenation in patients with much compromised respiratory system [29]. For this reason, people and in particular pregnant women with a weak immune system should take into account preventive measures to protect their health [6].

5. CONCLUSIONS

In conclusion, despite the scarcity of available data, current recommendations for the management of hypertension-related disorders in pregnancy remain valid since the risk of pharmacological interaction with currently tested anti-SARS-CoV-2 medications is relatively low.

Acknowledgements

Funding - This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of Interest - None declared.
References

1. Khan S, Peng L, Siddique R, Nabi G, Nawsherwan, Xue M, Liu J, Han G. Impact of COVID-19 infection on pregnancy outcomes and the risk of maternal-to-neonatal intrapartum transmission of COVID-19 during natural birth. Infect Control Hosp Epidemiol. 2020 Jun;41(6):748-750. doi: 10.1017/ice.2020.84.

2. World Health Organization. Coronavirus. Available from: https://www.who.int/health-topics/coronavirus. Accessed 17 Mar 2020.

3. Liu H, Wang LL, Zhao SJ, Kwak-Kim J, Mor G, Liao AH. Why are pregnant women susceptible to COVID-19? An immunological viewpoint. J Reprod Immunol. 2020;139:103122. doi: 10.1016/j.jri.2020.103122. [Epub ahead of print]

4. Qiao J. What are the risks of COVID-19 infection in pregnant women? Lancet. 2020;395(10226):760-762. doi: 10.1016/S0140-6736(20)30365-2.

5. Rajewska A, Mikołajek-Bedner W, Lebdowicz-Knul J, Sokolowska M, Kwiatkowski S, Torbé A. COVID-19 and pregnancy - where are we now? A review. J Perinat Med. 2020;48(5):428-434. doi: 10.1515/jpm-2020-0132.

6. Omer S, Ali S, Babar ZUD. Preventive measures and management of COVID-19 in pregnancy. Drugs Ther Perspect. 2020;1-4. doi: 10.1007/s40267-020-00725-x. [Epub ahead of print]

7. Zhao X, Jiang Y, Zhao Y, Xi H, Liu C, Qu F, Feng X. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening. Eur J Clin Microbiol Infect Dis. 2020;39(7):1209-1220. doi: 10.1007/s10096-020-03897-6.

8. Khan S, Jun L, Nawsherwan, Siddique R, Li Y, Han G, Xue M, Nabi G, Liu J. Association of COVID-19 with pregnancy outcomes in health-care workers and general women. Clin Microbiol Infect. 2020 Jun;26(6):788-790. doi: 10.1016/j.cmi.2020.03.034.
9. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong Q, Liao J, Yang H, Hou W, Zhang Y. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809-815. doi: 10.1016/S0140-6736(20)30360-3.

10. Maleki Dana P, Kolahdooz F, Sadoughi F, Moazzami B, Chaichian S, Asemi Z. COVID-19 and pregnancy: a review of current knowledge. Infez Med. 2020;28(suppl 1):46-51.

11. Zimmermann P, Curtis N. COVID-19 in Children, Pregnancy and Neonates: A Review of Epidemiologic and Clinical Features. Pediatr Infect Dis J. 2020 Jun;39(6):469-477. doi: 10.1097/INF.0000000000002700.

12. Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC, Ng PC, Lam PW, Ho LC, To WW, Lai ST, Yan WW, Tan PY. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol. 2004 Jul;191(1):292-7. doi: 10.1016/j.ajog.2003.11.019.

13. Lam CM, Wong SF, Leung TN, Chow KM, Yu WC, Wong TY, Lai ST, Ho LC. A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome. BJOG. 2004 Aug;111(8):771-4. doi: 10.1111/j.1471-0528.2004.00199.x.

14. Favre G, Pomar L, Musso D, Baud D. 2019-nCoV epidemic: what about pregnancies? Lancet. 2020 Feb 22;395(10224):e40. doi: 10.1016/S0140-6736(20)30311-1.

15. World Health Organization (WHO). Clinical management of severe acute respiratory infection when Novel coronavirus (2019-nCoV) infection is suspected: Interim Guidance. 2020. https://www.who.int/publications-detail/clinical-management-of
severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed Apr 20, 2020

16. Bellos I, Pergialiotis V, Papapanagiotou A, Loutradis D, Daskalakis G. Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network meta-analysis. Am J Obstet Gynecol. 2020 Mar 18. pii: S0002-9378(20)30338-0. doi: 10.1016/j.ajog.2020.03.016. [Epub ahead of print] Review.

17. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM, Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini T, Swan L, Warnes CA; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018 Sep 7;39(34):3165-3241. doi: 10.1093/eurheartj/ehy340.

18. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019;133(1):e1-e25. doi: 10.1097/AOG.0000000000003018.

19. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ [Internet]. 2020 Mar 17 [cited 2020 Mar 26];368. Available from: https://www.bmj.com/content/368/bmj.m1086

20. Voiriot G, Chalumeau M, Messika J, Basille D, Philippe B, Ricard JD, Andrejak C, Jounieaux V, Sanchez O, Fartoukh M. Risques associés à la prise d’anti-inflammatoires non stéroidiens au cours de la pneumonie [Risks associated with the use of non-steroidal anti-inflammatory drugs during pneumonia]. Rev Mal Respir. 2018 Apr;35(4):430-440. French. doi: 10.1016/j.rmr.2017.12.003.

14
21. Kwiatkowski S, Borowski D, Kajdy A, Poon LC, Rokita W, Wielgos M. Why we should not stop giving aspirin to pregnant women during the COVID-19 pandemic. Ultrasound Obstet Gynecol. 2020 Jun;55(6):841-843. doi: 10.1002/uog.22049.

22. Clark AR. MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids? J Endocrinol. 2003;178(1):5-12.

23. Galli M, Andreotti F, D'Amario D, Vergallo R, Vescovo GM, Giraldi L, Migliaro S, Ameri P, Porto I, Crea F. Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2020 Jan;6(1):43-56. doi: 10.1093/ehjcvp/pvz031.

24. Updated: WHO Now Doesn’t Recommend Avoiding Ibuprofen For COVID-19 Symptoms [Internet]. [cited 2020 Mar 23]. Available from: https://www.sciencealert.com/who-recommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms

25. Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, Howard VJ, Lichtman JH, Lisabeth LD, Piña IL, Reeves MJ, Rexrode KM, Saposnik G, Singh V, Towfighi A, Vaccarino V, Walters MR; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council for High Blood Pressure Research. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 May;45(5):1545-88. doi: 10.1161/01.str.0000442009.06663.48. Epub 2014 Feb 6. Erratum in: Stroke. 2014 Oct;45(10);e214. Erratum in: Stroke.2014 May;45(5):e95.
26. Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, De Clercq E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem. 2006;49:2845-2849.

27. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. doi: 10.1038/s41421-020-0156-0.

28. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271. doi: 10.1038/s41422-020-0282-0.

29. Liang H, Acharya G. Novel corona virus disease (COVID-19) in pregnancy: What clinical recommendations to follow? Acta Obstet Gynecol Scand. 2020;99(4):439-442. doi: 10.1111/aogs.13836.

30. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016 Jun;123(6):1386-94. doi: 10.1016/j.ophtha.2016.01.058.

31. Seo MR, Chae J, Kim YM, Cha HS, Choi SJ, Oh S, Roh CR. Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. Lupus. 2019 May;28(6):722-730. doi: 10.1177/0961203319843343.

32. Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus. 2006;15(3):148-55.

33. Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. Drugs. 2010;70(1):41-56. doi: 10.2165/11530710-000000000-00000.
34. Maisch B, Lamparter S, Ristić A, Pankuweit S. Schwangerschaft und Kardiomyopathie [Pregnancy and cardiomyopathies]. Herz. 2003 May;28(3):196-208. German. doi: 10.1007/s00059-003-2468-x.

35. Thachil J. The versatile heparin in COVID-19. J Thromb Haemost. 2020 May;18(5):1020-1022. doi: 10.1111/jth.14821.

36. Asakura H, Ogawa H. Potential of heparin and nafamostat combination therapy for COVID-19. J Thromb Haemost. 2020 Jun;18(6):1521-1522. doi: 10.1111/jth.14858.

37. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Available from: https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance (last access 2020 Apr 25)

38. Maille N, Gokina N, Mandalà M, Colton I, Osol G. Mechanism of hydralazine-induced relaxation in resistance arteries during pregnancy: Hydralazine induces vasodilation via a prostacyclin pathway. Vascul Pharmacol. 2016 Mar;78:36-42. doi: 10.1016/j.vph.2015.07.009.

39. Ashokka B, Loh MH, Tan CH, Su LL, Young BE, Lye DC, Biswas A, Illanes SE, Choolani M. Care of the pregnant woman with coronavirus disease 2019 in labor and delivery: anesthesia, emergency cesarean delivery, differential diagnosis in the acutely ill parturient, care of the newborn, and protection of the healthcare personnel. Am J Obstet Gynecol. 2020 Jul;223(1):66-74.e3. doi: 10.1016/j.ajog.2020.04.005.

40. Shi X, Lu Y, Li R, Tang Y, Shi N, Song F, Shan F, Chen G, Song P, Shi Y. Evaluation of antiviral therapies for coronavirus disease 2019 pneumonia in Shanghai, China. J Med Virol. 2020 Apr 16:10.1002/jmv.25893. doi: 10.1002/jmv.25893.

41. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li
H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282.

42. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63(8):769-802.

43. Baeza MT, Merino E, Boix V, Climent E. Nifedipine-lopinavir/ritonavir severe interaction: a case report. AIDS. 2007 Jan 2;21(1):119-20. doi: 10.1097/QAD.0b013e3280117f6f.

44. China National Health Commission. National health commission of the people’s republic of China. Chinese clinical guidance for covid-19 pneumonia diagnosis and treatment (7th edition). (April 22, 2020; date last accessed).

45. Rahnemaei FA, Fashami MA, Abdi F, Abbasi M. Factors effective in the prevention of Preeclampsia: A systematic review. Taiwan J Obstet Gynecol. 2020 Mar;59(2):173-182. doi: 10.1016/j.tjog.2020.01.002.

46. McLaughlin K, Baczyk D, Potts A, Hladunewich M, Parker JD, Kingdom JC. Low Molecular Weight Heparin Improves Endothelial Function in Pregnant Women at High Risk of Preeclampsia. Hypertension. 2017 Jan;69(1):180-188. doi: 10.1161/HYPERTENSIONAHA.116.08298.

47. Lipowsky HH, Lescanic A. Inhibition of inflammation induced shedding of the endothelial glycocalyx with low molecular weight heparin. Microvasc Res. 2017;112:72-78. doi: 10.1016/j.mvr.2017.03.007.
48. Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K, Goudarzi H. Macrolide treatment for COVID-19: Will this be the way forward? Biosci Trends. 2020 May 21;14(2):159-160. doi: 10.5582/bst.2020.03058.

49. Wen J, Zhang X, Li C. Clinical Effect of Low Molecular Weight Heparin Sodium Combined with Magnesium Sulfate in the Treatment of Patients with Severe Preeclampsia. J Coll Physicians Surg Pak. 2019;29(2):119-122. doi: 10.29271/jcpsp.2019.02.119.

50. Browne PC, Linfert JB, Perez-Jorge E. Successful Treatment of Preterm Labor in Association with Acute COVID-19 Infection. Am J Perinatol. 2020 Jun;37(8):866-868. doi: 10.1055/s-0040-1709993.

51. Fogacci S, Fogacci F, Banach M, Michos ED, Hernandez AV, Lip GYH, Blaha MJ, Toth PP, Borghi C, Cicero AFG; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Vitamin D supplementation and incident preeclampsia: A systematic review and meta-analysis of randomized clinical trials. Clin Nutr. 2020 Jun;39(6):1742-1752. doi: 10.1016/j.clnu.2019.08.015.

52. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020 Jul;39(7):2055-2062. doi: 10.1007/s10067-020-05073-9.

53. Teymoori-Rad M, Shokri F, Salimi V, Marashi SM. The interplay between vitamin D and viral infections. Rev Med Virol. 2019 Mar;29(2):e2032. doi: 10.1002/rmv.2032.

54. Singh SK, Jain R, Singh S. Vitamin D deficiency in patients with diabetes and COVID-19 infection. Diabetes Metab Syndr. 2020 Jul 3;14(5):1033-1035. doi: 10.1016/j.dsx.2020.06.071. Epub ahead of print.

55. Panagiotou G, Tee SA, Ihsan Y, Athar W, Marchitelli G, Kelly D, Boot CS, Stock N, Macfarlane J, Martineau AR, Burns G, Quinton R. Low serum 25-hydroxyvitamin D
(25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity. Clin Endocrinol (Oxf). 2020 Jul 3:10.1111/cen.14276. doi: 10.1111/cen.14276.

56. Yusrawati, Saputra NPK, Lipoeto NI, Machmud R. Analyses of Nutrients and Body Mass Index as Risk Factor for Preeclampsia. J Obstet Gynaecol India. 2017 Dec;67(6):409-413. doi: 10.1007/s13224-017-0982-7.

57. Wang Z, Wang C, Qiu J, Ni Y, Chai S, Zhou L, Li J, Yan B, Yang J, Liu Q. The Association between Dietary Vitamin C/E and Gestational Hypertensive Disorder: A Case-Control Study. J Nutr Sci Vitaminol (Tokyo). 2018;64(6):454-465. doi: 10.3177/jnsv.64.454.

58. Carr AC. A new clinical trial to test high-dose vitamin C in patients with COVID-19. Crit Care. 2020;24(1):133. doi: 10.1186/s13054-020-02851-4.

59. Donald S, Sharples K, Barson D, Horsburgh S, Parkin L. Prescription medicines with potential for foetal harm: dispensing before and during pregnancy in New Zealand, 2005-2015. Eur J Clin Pharmacol. 2020 Apr 4. doi: 10.1007/s00228-020-02868-2. [Epub ahead of print]

60. Liu F, Zhu Y, Zhang J, Li Y, Peng Z. Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial. BMJ Open. 2020 Jul 8;10(7):e039519. doi: 10.1136/bmjopen-2020-039519.

61. Beigmohammadi MT, Bitarafan S, Hoseindokht A, Abdollahi A, Amoozadeh L, Mahmoodi Ali Abadi M, Foroumandi M. Impact of vitamins A, B, C, D, and E supplementation on improvement and mortality rate in ICU patients with coronavirus-19: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Jul 6;21(1):614. doi: 10.1186/s13063-020-04547-0.
62. Della Gatta AN, Rizzo R, Pilu G, Simonazzi G. Coronavirus disease 2019 during pregnancy: a systematic review of reported cases. Am J Obstet Gynecol. 2020 Jul;223(1):36-41. doi: 10.1016/j.ajog.2020.04.013.

63. Saums MK, King CC, Adams JC, Sheth AN, Badell ML, Young M, Yee LM, Chadwick EG, Jamieson DJ, Haddad LB. Combination Antiretroviral Therapy and Hypertensive Disorders of Pregnancy. Obstet Gynecol. 2019 Dec;134(6):1205-1214. doi: 10.1097/AOG.0000000000003584.

64. Webster K, Fishburn S, Maresh M, Findlay SC, Chappell LC; Guideline Committee. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance. BMJ. 2019 Sep 9;366:l5119. doi: 10.1136/bmj.l5119.

65. Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, Gao H, Liu L, Zhang G. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020 Dec;9(1):757-760. doi: 10.1080/22221751.2020.1746200.

66. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, Xia M, Chen MM, Cheng X, Zhang X, Guo D, Peng Y, Ji YX, Chen J, She ZG, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu M, Chen M, Zhang XJ, Wang X, Touyz RM, Xia J, Zhang BH, Huang X, Yuan Y, Rohit L, Liu PP, Li H. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134.

67. LaCourse S, John-Stewart G, Adams Waldorf KM. Importance of Inclusion of Pregnant and Breastfeeding Women in COVID-19 Therapeutic Trials. Clin Infect Dis. 2020 Jul 28;71(15):879-881. doi: 10.1093/cid/ciaa444.
68. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J Clin Med. 2020;9(5):1417. doi: 10.3390/jcm9051417.

69. Amraei R, Rahimi N. COVID-19, Renin-Angiotensin System and Endothelial Dysfunction. Cells. 2020;9(7):1652. doi: 10.3390/cells9071652.

70. Pearce L, Davidson SM, Yellon DM. The cytokine storm of COVID-19: a spotlight on prevention and protection. Expert Opin Ther Targets. 2020;1-8. doi: 10.1080/14728222.2020.1783243.

Figure legends

Figure 1 - Anti-hypertensive drugs interaction with anti-COVID-19 medications.

LMWH= Low molecular weight heparin; NSAIDs= Non-steroidal anti-inflammatory drugs.
